PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru.\', \'Programa de Atención Domiciliaria - EsSalud, Lima, Peru.\', \'Asociación para el Desarrollo de la Investigación Estudiantil en Ciencias de la Salud (ADIECS), Lima, Peru.\', \'Facultad de Medicina de San Fernando, Universidad Nacional Mayor de San Marcos, Lima, Peru.\', \'Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group, University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1002/pds.5234
?:doi
?:hasPublicationType
?:journal
  • Pharmacoepidemiology and drug safety
is ?:pmid of
?:pmid
?:pmid
  • 33772933
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.329
?:rankingScore_hIndex
  • 80
is ?:relation_isRelatedTo_publication of
?:title
  • QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all